State of progress in treating cystic fibrosis respiratory disease.

BMC Med · 2012 · PMC3425089 · PMID 22883684

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Aerosolized amiloride (an epithelial sodium channel blocker with a short half-life) not only had no clinical benefit, it showed a trend toward poorer lung function in the treated patients [ 77 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.